Biotech firm Novavax Inc. (NVAX) expects to release test results only in early 2021 for its NVX-CoV2373 COVID-19 vaccine. At this time, its major rivals are already able to begin selling their vaccines. It could seem that in the competition, Novavax lost. The business could however, become one of the market leaders for COVID-19 vaccines in the long term.
Investors currently have no data on the NVX-CoV2373 vaccine from Novavax. In particular, as well as final details on the safety profile, there is no information on its efficacy in the last phases of the analysis.
The early results of Novavax, however were so strong that many critics called the company’s Covid-19 vaccine probably the best in its class. Furthermore the vaccine has proved to be effective at all levels of research so far.
But the key benefit of Novavax’s NVX-CoV2373 vaccine is that it can be paired with the seasonal flu vaccine, which is also being produced by Novavax. In other words, a combination vaccine that offers more full security will theoretically be launched by the company. The latest coronavirus may become as seasonal as the flu, which would entail an annual mass vaccination, according to some researchers. This suggests that for patients in this case, the Novavax combination vaccine could be a safer option. By contrast, neither Moderna nor Pfizer currently have a ready-made flu vaccine and in a short period of time they will not be able to launch a competing development.
The ability to develop a combined vaccine could place Novavax in a leading position in the field of seasonal disease prevention.
Novavax Inc. (NVAX) shares have risen by more than 2,918 percent since the beginning of the year to have a market capitalization of about $7.82 billion. The stock was worth $120.12 at ring of the bell on Tuesday with a day’s loss of -2.44%.